Roth Capital Forecasts Nuwellis’ Q1 Earnings (NASDAQ:NUWE)

Nuwellis, Inc. (NASDAQ:NUWE) – Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Nuwellis in a report issued on Monday, January 13th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings of ($0.30) per share for the quarter. The consensus estimate for Nuwellis’ current full-year earnings is ($9.91) per share. Roth Capital also issued estimates for Nuwellis’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.18) EPS, FY2027 earnings at $0.41 EPS and FY2029 earnings at $1.78 EPS.

Nuwellis (NASDAQ:NUWE) last posted its quarterly earnings data on Monday, November 11th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of ($0.88) by $2.62. The company had revenue of $2.37 million during the quarter, compared to analysts’ expectations of $2.40 million. Nuwellis had a negative net margin of 169.54% and a negative return on equity of 28,159.25%. During the same period in the prior year, the company posted ($63.29) earnings per share.

Nuwellis Stock Up 1.4 %

Shares of NASDAQ NUWE opened at $1.09 on Wednesday. The firm has a market cap of $4.74 million, a PE ratio of -0.01 and a beta of 0.32. The company’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $1.86. Nuwellis has a 12-month low of $0.92 and a 12-month high of $27.61.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.